Ultragenyx Pharmaceutical Inc. (RARE) Reaches $55.95 After 7.00% Up Move; Blackrock Multi-sector Income Trust (BIT) Has 1.37 Sentiment

April 17, 2018 - By Winifred Garcia

Blackrock Multi-sector Income Trust (BIT) investors sentiment increased to 1.37 in 2017 Q4. It’s up 0.24, from 1.13 in 2017Q3. The ratio is more positive, as 26 investment managers opened new or increased positions, while 19 sold and decreased their equity positions in Blackrock Multi-sector Income Trust. The investment managers in our database now own: 8.36 million shares, up from 8.03 million shares in 2017Q3. Also, the number of investment managers holding Blackrock Multi-sector Income Trust in top ten positions was flat from 0 to 0 for the same number . Sold All: 7 Reduced: 12 Increased: 17 New Position: 9.

The stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is a huge mover today! The stock increased 3.96% or $2.13 during the last trading session, reaching $55.95. About 358,996 shares traded. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has declined 29.39% since April 17, 2017 and is downtrending. It has underperformed by 40.94% the S&P500.The move comes after 6 months positive chart setup for the $2.78B company. It was reported on Apr, 17 by Barchart.com. We have $59.87 PT which if reached, will make NASDAQ:RARE worth $194.25M more.

Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company has market cap of $2.78 billion. The firm is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It currently has negative earnings. The Company’s biologics product candidates also comprise recombinant human beta -glucuronidase , an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis.

Analysts await Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to report earnings on May, 3. They expect $-0.76 EPS, up 53.37% or $0.87 from last year’s $-1.63 per share. After $-2.27 actual EPS reported by Ultragenyx Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts -66.52% EPS growth.

Investors sentiment increased to 1.25 in 2017 Q4. Its up 0.06, from 1.19 in 2017Q3. It is positive, as 14 investors sold Ultragenyx Pharmaceutical Inc. shares while 42 reduced holdings. 19 funds opened positions while 51 raised stakes. 42.32 million shares or 6.46% more from 39.75 million shares in 2017Q3 were reported. Moreover, Sei has 0% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for 2,483 shares. 1,300 were accumulated by Peak6 Invs Limited Partnership. First Advsrs L P has invested 0.09% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Smith Asset Mgmt Gru Ltd Partnership has invested 0.01% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Prudential Fincl accumulated 0% or 30,334 shares. Deutsche Fincl Bank Ag reported 183,677 shares. Wells Fargo Mn invested 0% of its portfolio in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Clearbridge Limited Liability Company has invested 0% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Rmb Management Limited Liability holds 0.05% or 43,733 shares in its portfolio. Blackrock reported 0.01% of its portfolio in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Fortaleza Asset Mgmt Inc holds 1,640 shares or 0.48% of its portfolio. New York State Common Retirement Fund invested in 43,200 shares or 0% of the stock. Automobile Association accumulated 26,767 shares. Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Millennium Mngmt Lc, a New York-based fund reported 123,835 shares.

Among 22 analysts covering Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), 15 have Buy rating, 1 Sell and 6 Hold. Therefore 68% are positive. Ultragenyx Pharmaceutical Inc has $126 highest and $55.0 lowest target. $74.45’s average target is 33.07% above currents $55.95 stock price. Ultragenyx Pharmaceutical Inc had 62 analyst reports since July 27, 2015 according to SRatingsIntel. The rating was downgraded by SunTrust to “Hold” on Wednesday, August 23. Wedbush downgraded Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) rating on Wednesday, April 19. Wedbush has “Neutral” rating and $75 target. On Tuesday, May 10 the stock rating was maintained by Wedbush with “Outperform”. The firm has “Outperform” rating by Robert W. Baird given on Friday, November 3. The rating was initiated by Bank of America with “Buy” on Tuesday, June 28. The firm has “Buy” rating given on Monday, December 4 by Jefferies. As per Wednesday, February 21, the company rating was maintained by Stifel Nicolaus. The stock has “Neutral” rating by Citigroup on Tuesday, January 12. The rating was maintained by Stifel Nicolaus on Tuesday, August 22 with “Buy”. H.C. Wainwright maintained the shares of RARE in report on Tuesday, August 8 with “Hold” rating.

Shaker Financial Services Llc holds 1.05% of its portfolio in BlackRock Multi-Sector Income Trust for 121,886 shares. Rivernorth Capital Management Llc owns 634,189 shares or 0.8% of their US portfolio. Moreover, E&G Advisors Lp has 0.73% invested in the company for 95,270 shares. The Georgia-based Vident Investment Advisory Llc has invested 0.43% in the stock. Jaffetilchin Investment Partners Llc, a Florida-based fund reported 55,876 shares.

The stock decreased 0.15% or $0.02 during the last trading session, reaching $16.93. About 81,500 shares traded. BlackRock Multi-Sector Income Trust (BIT) has declined 2.20% since April 17, 2017 and is downtrending. It has underperformed by 13.75% the S&P500.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.